Benefortin Flavoured Tablets are for the treatment of congestive heart failure in dogs and cats.
Benefortin Flavoured Tablets 2.5mg for Dogs and Cats is for the treatment of congestive heart failure in dogs and cats. Each tablet contains 2.5mg benazepril hydrochloride (equivalent...[More info]
Benefortin Flavoured Tablets 5mg for Dogs is for the treatment of congestive heart failure in dogs. Each tablet contains 5.0mg benazepril hydrochloride (equivalent to 4.60mg benazepril)....[More info]
Benefortin Flavoured Tablets 20mg for Dogs is for the treatment of congestive heart failure in dogs. Each tablet contains 20.0mg benazepril hydrochloride (equivalent to 18.4mg benazepril)....[More info]
Dosage and Administration
Oral use once daily, with or without food.
Cats: The dose is 0.46 mg benazepril/kg bw per day, corresponding to 0.50 mg of benazepril hydrochloride/kg bw per day equivalent to 1 tablet per 5Kg bodyweight.
Dogs: The dose is 0.23 mg benazepril/kg bw per day, corresponding to 0.25 mg of benazepril hydrochloride/kg bw per day which may be doubled if judged clinically necessary and advised by the veterinary surgeon.
Contra-indications, warnings, etc
Do not use in any dog that has evidence of cardiac output failure due to aortic stenosis. Do not use in animals known to be hypersensitive to the active substance or to any of the excipients. No evidence of renal toxicity to benazepril has been observed in dogs or cats. However, as is routine in cases of renal insufficiency, it is recommended to monitor plasma creatinine and urea during therapy. The efficacy and safety of benazepril has not been established in cats below 2.5 kg body weight. Benazepril hydrochloride is well tolerated in the target species. Transient reversible hypotension may occur in cases of accidental overdosage. Therapy should consist of intravenous infusion of warm, isotonic saline. In normal cats, a 10-fold overdosage daily for one year was asymptomatic. Laboratory studies in rats have shown evidence of embryotoxic effects (malformation of urinary tract) of benazepril at non maternotoxic doses. Laboratory studies in rats as well as human observations have shown evidence of teratogenicity. The safety of benazepril hydrochloride has not been tested in breeding, pregnant or lactating dogs and cats. Do not use in breeding or lactating animals or in females intended for reproduction. Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg for 52 weeks. Some dogs may exhibit transient signs of fatigue or dizziness. At the start of treatment, a decrease of blood pressure may occur. Benazepril may lead to increased plasma creatinine concentrations. Benazepril may increase food consumption and body weight in cats. Emesis, anorexia, diarrhoea and lethargy have been reported very rarely in this species. In dogs with heart failure, benazepril has been given in combination with digoxin, diuretics and anti-arrhythmic drugs without demonstrable adverse interactions. In man, the combination of ACE inhibitors and NSAIDs can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of benazepril and other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc) should be monitored closely and treated as necessary. Interactions with potassium-preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using benazepril in combination with a potassium-sparing diuretic as life threatening reactions are a possibility.